66 related articles for article (PubMed ID: 24327148)
21. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.
Thol F; Friesen I; Damm F; Yun H; Weissinger EM; Krauter J; Wagner K; Chaturvedi A; Sharma A; Wichmann M; Göhring G; Schumann C; Bug G; Ottmann O; Hofmann WK; Schlegelberger B; Heuser M; Ganser A
J Clin Oncol; 2011 Jun; 29(18):2499-506. PubMed ID: 21576631
[TBL] [Abstract][Full Text] [Related]
22. The biology and clinical impact of genetic lesions in myeloid malignancies.
Lindsley RC; Ebert BL
Blood; 2013 Nov; 122(23):3741-8. PubMed ID: 23954890
[TBL] [Abstract][Full Text] [Related]
23. Targeted therapy of acute myeloid leukemia.
Carneiro BA; Altman JK; Kaplan JB; Ossenkoppele G; Swords R; Platanias LC; Giles FJ
Expert Rev Anticancer Ther; 2015 Apr; 15(4):399-413. PubMed ID: 25623136
[TBL] [Abstract][Full Text] [Related]
24. Whole-exome sequencing enhances prognostic classification of myeloid malignancies.
Ruffalo M; Husseinzadeh H; Makishima H; Przychodzen B; Ashkar M; Koyutürk M; Maciejewski JP; LaFramboise T
J Biomed Inform; 2015 Dec; 58():104-113. PubMed ID: 26453823
[TBL] [Abstract][Full Text] [Related]
25. Impact of mutations in epigenetic modifiers in acute myeloid leukemia: A systematic review and meta-analysis.
Al-Bulushi F; Al-Riyami R; Al-Housni Z; Al-Abri B; Al-Khabori M
Front Oncol; 2022; 12():967657. PubMed ID: 36518313
[TBL] [Abstract][Full Text] [Related]
26. Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium.
Tefferi A; Abdel-Wahab O; Cervantes F; Crispino JD; Finazzi G; Girodon F; Gisslinger H; Gotlib J; Kiladjian JJ; Levine RL; Licht JD; Mullally A; Odenike O; Pardanani A; Silver RT; Solary E; Mughal T
Blood Cancer J; 2011 Mar; 1(3):e7. PubMed ID: 23471017
[TBL] [Abstract][Full Text] [Related]
27. Effects of Black Raspberry Supplementation on Methylation Pathways in
Dong A; Huang YW; Niu B; Liu R; Wu W; Gao H; Yu J; Wang LS
J Cancer Prev; 2023 Dec; 28(4):212-218. PubMed ID: 38205364
[TBL] [Abstract][Full Text] [Related]
28. ASXL1 Gene in AML.
Hurtado R; Guirales F; Tirado CA
J Assoc Genet Technol; 2021; 47(2):60-68. PubMed ID: 34140438
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic regulation of miRNA-124 and multiple downstream targets is associated with treatment response in myeloid malignancies.
Liu H; Pattie P; Chandrasekara S; Spencer A; Dear AE
Oncol Lett; 2016 Sep; 12(3):2175-2180. PubMed ID: 27602159
[TBL] [Abstract][Full Text] [Related]
30. Complete mutational spectrum of the autophagy interactome: a novel class of tumor suppressor genes in myeloid neoplasms.
Visconte V; Przychodzen B; Han Y; Nawrocki ST; Thota S; Kelly KR; Patel BJ; Hirsch C; Advani AS; Carraway HE; Sekeres MA; Maciejewski JP; Carew JS
Leukemia; 2017 Feb; 31(2):505-510. PubMed ID: 27773925
[No Abstract] [Full Text] [Related]
31. Somatic PHF6 mutations in 1760 cases with various myeloid neoplasms.
Mori T; Nagata Y; Makishima H; Sanada M; Shiozawa Y; Kon A; Yoshizato T; Sato-Otsubo A; Kataoka K; Shiraishi Y; Chiba K; Tanaka H; Ishiyama K; Miyawaki S; Mori H; Nakamaki T; Kihara R; Kiyoi H; Koeffler HP; Shih LY; Miyano S; Naoe T; Haferlach C; Kern W; Haferlach T; Ogawa S; Yoshida K
Leukemia; 2016 Nov; 30(11):2270-2273. PubMed ID: 27479181
[No Abstract] [Full Text] [Related]
32. Genetic alterations in 47 patients with a novel myelodysplastic syndrome diagnosis at a single center.
Zhao P; Qin J; Liu W; Quan R; Xiao H; Liu C; Li L; Lv Y; Zhu Q; Wang H; Guo X; Wang J; Hu X
Oncol Lett; 2019 Nov; 18(5):5077-5084. PubMed ID: 31612018
[TBL] [Abstract][Full Text] [Related]
33. Novel therapeutic strategy based on genetic and epigenetic abnormalities for myeloid neoplasms.
Yamauchi T
Int J Clin Oncol; 2019 Aug; 24(8):883-884. PubMed ID: 31104174
[No Abstract] [Full Text] [Related]
34. [Research on molecular markers for epigenetic changes in myeloid malignancies].
Li L; Sun XM
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Dec; 30(6):687-92. PubMed ID: 24327148
[TBL] [Abstract][Full Text] [Related]
35. The role of mutations in epigenetic regulators in myeloid malignancies.
Shih AH; Abdel-Wahab O; Patel JP; Levine RL
Nat Rev Cancer; 2012 Sep; 12(9):599-612. PubMed ID: 22898539
[TBL] [Abstract][Full Text] [Related]
36. The Impact of Epigenetic Modifications in Myeloid Malignancies.
Venney D; Mohd-Sarip A; Mills KI
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34065087
[TBL] [Abstract][Full Text] [Related]
37. [Epigenetic dysregulation in myelodysplastic syndromes].
Sashida G
Rinsho Ketsueki; 2017; 58(10):1809-1817. PubMed ID: 28978819
[TBL] [Abstract][Full Text] [Related]
38. The evolving molecular genetic landscape in acute myeloid leukaemia.
Sanders MA; Valk PJ
Curr Opin Hematol; 2013 Mar; 20(2):79-85. PubMed ID: 23380602
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
